美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

2倍做多NVO ETF-Defiance

10.72

+0.31002.98%

盤前：10.860.1400+1.31%04:13 EDT

成交量：75.59萬

成交額：797.01萬

市值：4,650.44萬

市盈率：- -

高：10.75

開：10.38

低：10.32

收：10.41

52周最高：79.52

52周最低：9.38

股本：433.81萬

流通股本：433.81萬

量比：0.48

換手率：17.42%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

反彈50%只是開始？深度覆盤HIMS與藥王的「世紀大和解」

Hims & Hers Health(HIMS)盤前漲8% 日前與諾和諾德建立新的合作伙伴關係

$365億新「藥王」誕生！減肥「神藥」領跑，「自免」新星高漲50%，潛力市場衝刺100億大關

FDA 連發多份 CRL，開年大批新藥上市申請已遭拒

FDA震怒？！諾和諾德瞞報死亡、中風與自殺傾向，司美、利拉魯肽遭警告

諾和諾德遇 FDA 監管提醒，GLP-1 藥物不良事件報告待完善

细胞基因研究圈

諾和諾德旗下「問題」工廠，又一家藥企遭殃

生物制药小编

諾和諾德(NVO)股票3月10日盤中下跌3.13%：原因全解讀

TradingKey中文

美股異動丨諾和諾德跌3.3%，因未報告旗下減肥藥的所有疑似副作用接獲FDA警告信

Hims & Hers與諾和諾德達成和解

环球市场播报

跨國藥企2025年成績單：「藥王」易主，創新資產交易創新高

21世纪经济报道

Hims & Hers Health盤前續升逾2%，諾和諾德旗下明星減肥藥將登陸平台

花旗上調Hims & Hers Health(HIMS.US)評級至「中性」看好諾和諾德協議下的合規溢價

3月10日美股成交額前20：HIMS與諾和諾德達成合作，股價大漲逾40%

环球市场播报

諾和諾德盤中異動股價大漲3.00%報39.74美元

分析師：Hims & Hers本身不會通過諾和諾德的GLP-1s藥物盈利

Hims與諾和諾德合作或引發短期逆風——市場快訊

諾和諾德確認將在HIMS & HERS平台上銷售WEGOVY、OZEMPIC產品。

美股異動丨Hims盤前飆漲55%，與諾和諾德達成減肥藥授權協議

諾和諾德全球首創新藥在華獲批；羅氏公布amylin減重臨床數據

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NVOX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":10.72,"timestamp":1773691200000,"preClose":10.41,"halted":0,"volume":755890,"hourTrading":{"tag":"盘前","latestPrice":10.86,"preClose":10.72,"latestTime":"04:13 EDT","volume":212,"amount":2293.360032,"timestamp":1773735220155,"change":0.14,"changeRate":0.01306,"amplitude":0.007463},"delay":0,"changeRate":0.029779058597502447,"floatShares":4338101,"shares":4338101,"eps":0,"marketStatus":"盤前交易","change":0.31,"latestTime":"03-17 04:16:02 EDT","open":10.38,"high":10.75,"low":10.32,"amount":7970058.8066,"amplitude":0.041306,"askPrice":10.96,"askSize":500,"bidPrice":10.87,"bidSize":2100,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1773754200000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":10.72,"sharesOutstanding":4098101,"nav":10.42,"aum":45203012.42,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":10.86,"preClose":10.72,"latestTime":"04:13 EDT","volume":212,"amount":2293.360032,"timestamp":1773735220155,"change":0.14,"changeRate":0.01306,"amplitude":0.007463},"postHourTrading":{"tag":"盘后","latestPrice":10.72,"preClose":10.72,"latestTime":"19:53 EDT","volume":13108,"amount":140304.8924,"timestamp":1773705228898,"change":0,"changeRate":0,"amplitude":0.008396},"volumeRatio":0.48030656114125203,"impliedVol":0.7631,"impliedVolPercentile":0.3896},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":4338101,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.48030656114125203,"shares":4338101,"dividePrice":0,"high":10.75,"amplitude":0.041306,"preClose":10.41,"low":10.32,"week52Low":9.38,"pbRate":"--","week52High":79.52,"institutionHeld":0,"latestPrice":10.72,"committee":0.615385,"eps":0,"divideRate":0,"volume":755890,"delay":0,"ttmEps":0,"open":10.38,"prevYearClose":21.89,"prevWeekClose":10.41,"prevMonthClose":10.27,"prevQuarterClose":21.89,"fiveDayClose":11.5,"twentyDayClose":18.9,"sixtyDayClose":20.52},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619019014","title":"反彈50%只是開始？深度覆盤HIMS與藥王的「世紀大和解」","url":"https://stock-news.laohu8.com/highlight/detail?id=2619019014","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619019014?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 21:20","pubTimestamp":1773408035,"startTime":"0","endTime":"0","summary":"在狂热中保持一份清醒","market":"sg","thumbnail":"https://img3.gelonghui.com/3c716-ca1a8464-8f16-4866-ab41-c44262ef4bdf.jpg?guru_height=876&guru_width=1605&guru_size=79794","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/3c716-ca1a8464-8f16-4866-ab41-c44262ef4bdf.jpg?guru_height=876&guru_width=1605&guru_size=79794"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4071127","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4588","HIMS","IE00BZ1G4Q59.USD","BK4585","BK4532","HIMY","BK4196","NVOX","LU1093756168.USD","LU0154236417.USD","NVOH","LU1093756325.SGD","HIYY","IE00BKVL7J92.USD","BK4599","HMYY","BK4007"],"gpt_icon":1},{"id":"2618138250","title":"Hims & Hers Health(HIMS)盤前漲8% 日前與諾和諾德建立新的合作伙伴關係","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138250","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618138250?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 18:08","pubTimestamp":1773310089,"startTime":"0","endTime":"0","summary":"金吾财讯 | Hims & Hers Health 盘前涨8%，截至发稿，报27.950美元。消息面上，日前，Hims & Hers Health与诺和诺德建立新的合作伙伴关系，专注于提供品牌药物。两家公司于周一表示，诺和诺德已同意在Hims & Hers Health平台上销售其王牌药物Ozempic和Wegovy，其中包括备受欢迎的Wegovy口服片剂。同时，诺和诺德将撤回上个月针对Hims & Hers Health提起的诉讼。作为回报，Hims & Hers Health表示将不再为其仿制版诺和诺德药物投放广告。但如果医生认为患者有必要使用，该公司仍将销售Wegovy和Ozempic的复配版本。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/ZTgzYzFjMzMwYjg4MjEzNTY0MzUzNDIy.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZTgzYzFjMzMwYjg4MjEzNTY0MzUzNDIy.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"297963","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BZ1G4Q59.USD","BK4196","BK4588","BK4599","HIMS","LU1093756325.SGD","HIMY","LU1093756168.USD","BK4532","HIMZ","BK4007","LU0154236417.USD","HMYY","NVOX","IE00BKVL7J92.USD","HIYY","NVOH"],"gpt_icon":0},{"id":"2618917441","title":"$365億新「藥王」誕生！減肥「神藥」領跑，「自免」新星高漲50%，潛力市場衝刺100億大關","url":"https://stock-news.laohu8.com/highlight/detail?id=2618917441","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618917441?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 16:25","pubTimestamp":1773217553,"startTime":"0","endTime":"0","summary":"据梳理，TOP1产品销售额、TOP10产品销售额门槛对比2024年均有提升；替尔泊肽全球销售额超365亿美元，首次斩获“药王”宝座，司美格鲁肽以微弱差距排名第二；抗肿瘤赛道大热，帕博利珠单抗、达雷妥尤单抗、纳武利尤单抗成“三足鼎立”之势；自免新星加速崛起，利生奇珠单抗大涨50%；抗凝老将阿哌沙班坚守TOP4，HIV金标准比克恩丙诺稳健增长。全球新“药王”诞生！其中，BMS贡献约144.43亿美元的销售额，辉瑞的销售额约89.61亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163736a6b79845&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163736a6b79845&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BN8TJ469.HKD","LU0266013472.USD","LU2125154935.USD","NVOX","SG9999002224.SGD","LU0203347892.USD","LU1116320737.USD","LU0942090050.USD","IE0009355771.USD","LU1061106388.HKD","LU0058720904.USD","LU1069347547.HKD","NVO","LU1989772840.SGD","IE00BZ1G4Q59.USD","IE00BLSP4239.USD","LU1066053197.SGD","LU1934455277.USD","LU1974910355.USD","LU1941712264.USD","MRK","LU1066051811.HKD","LU2361044865.SGD","LU0154236417.USD","LU0965509101.SGD","SG9999001440.SGD","LU0098860793.USD","SG9999014575.USD","BK4599","LU1066051225.USD","BK4534","LU1941712348.USD","LU1983299246.USD","SG9999001176.USD","LU2112291526.USD","SG9999015341.SGD","LU0234572021.USD","LU0211331839.USD","LU1037948897.HKD","LU0320765646.SGD","LU1093756325.SGD","LU0965509010.AUD","LU0868494708.USD","IE00BSNM7G36.USD","LU2125154778.USD","LU0985320562.USD","LU0477156953.USD","NVOH","SG9999014542.SGD","LU2461242641.AUD","LU2089984988.USD","LU1699723380.USD","BK4532","SGXZ57979304.SGD","LU0203345920.USD","LU1037948541.HKD","BK4007","LU0965508806.USD","IE00BKVL7J92.USD","LU1023059063.AUD","IE000M9KFDE8.USD","LU1585245621.USD","LU1989772923.USD","LU1057294990.SGD","LU1917777945.USD","BK4585","LU1929549753.HKD","IE00BJJMRZ35.SGD","LU1066051498.USD","BK4559","LU0238689110.USD","LU0006306889.USD","LU1989771016.USD","LU0980610538.SGD","SG9999014567.USD","LU0130517989.USD","LU0070302665.USD","LU1035773651.USD","LU2023250843.SGD","LU1934455863.HKD","SG9999002232.USD","LU1116320901.HKD","BK4516","IE0002141913.USD","LU2106854487.HKD","LU1934455194.USD","LU0265550359.USD","IE00BBT3K403.USD","LU0265550946.USD","IE00B4R5TH58.HKD","LU0289739699.SGD","LU0648001328.SGD","LU2324357040.USD","IE00BJT1NW94.SGD","LLY","LU1162221912.USD","SG9999013999.USD","LU2361045086.USD","LU0130102774.USD","LU2361044949.HKD","LU2468319806.SGD","LU0965509283.SGD","LU0106261372.USD","LU0432979614.USD","BK4588","LU2360032135.SGD","LU2023250504.SGD","SG9999015358.SGD","LU1093756168.USD","LU0861579265.USD","IE00B2B36J28.USD","BK4533","IE00B1BXHZ80.USD","LU0208291251.USD","LU1430594728.SGD","LU0122379950.USD","SG9999014559.SGD","LU0868494617.USD","SG9999001176.SGD","LU1291159041.SGD","LU1571399168.USD","LU0320765489.SGD","BK4550","ABBV","IE00BLSP4452.SGD","LU1201861249.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":1},{"id":"2618157119","title":"FDA 連發多份 CRL，開年大批新藥上市申請已遭拒","url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618157119?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 14:39","pubTimestamp":1773211194,"startTime":"0","endTime":"0","summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4530","NVOH","NVOX","INCY","LU0757428866.USD","AZN","BK4532","IE00BKVL7J92.USD","BK4007","NVO","BK4585","LU0154236417.USD","LU0390134368.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4121","LU0128526141.USD","LU1815336091.USD","LU1093756325.SGD","BK4599","LU0029874061.USD","IE00BFMHRM44.USD","REGN","BK4588"],"gpt_icon":0},{"id":"2618153939","title":"FDA震怒？！諾和諾德瞞報死亡、中風與自殺傾向，司美、利拉魯肽遭警告","url":"https://stock-news.laohu8.com/highlight/detail?id=2618153939","media":"药闻天下","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618153939?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 12:33","pubTimestamp":1773203611,"startTime":"0","endTime":"0","summary":"事实上，这并非FDA的突击制裁，而是一场长达一年、最终崩盘的合规拉锯战。在过去整整一年里，诺和诺德信誓旦旦地向FDA提交了多达7次的整改进度报告。根据FDA的警告信披露，诺和诺德的安全数据库中存在大量令人脊背发凉的“漏报”案例：“患者说无关，我们就取消”：在Argus的1331385号病例中，一名使用利拉鲁肽的患者遭遇了中风导致残疾。诺和诺德斥巨资从Catalent手中收购的印第安纳州布卢明顿工厂，近期同样吃到了FDA的警告信。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311143523954825dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311143523954825dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","IE00BKVL7J92.USD","NVO","LU1093756168.USD","BK4599","BK4585","BK4532","LU1093756325.SGD","BK4588","NVOH","IE00BZ1G4Q59.USD","NVOX","LU0154236417.USD"],"gpt_icon":1},{"id":"2618399032","title":"諾和諾德遇 FDA 監管提醒，GLP-1 藥物不良事件報告待完善","url":"https://stock-news.laohu8.com/highlight/detail?id=2618399032","media":"细胞基因研究圈","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618399032?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 11:58","pubTimestamp":1773201494,"startTime":"0","endTime":"0","summary":"摘要：2026 年 3 月，丹麦药企诺和诺德美国新泽西普兰斯堡总部收到 FDA 正式警告信，核心问题集中在上市后不良药物事件 报告体系的合规性上。涉事产品包含司美格鲁肽等王牌 GLP-1 药物，FDA 直指其报告流程存在多处漏洞，且整改措施未达要求。检查结束当天，FDA 就向诺和诺德出具了Form 483 表格，清晰列出了其在药品副作用监测和报告环节的多项不合规问题。另外，诺和诺德对不良事件的医学审核周期过长，审核效率低下。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311125239a46036e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311125239a46036e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","BK4532","BK4590","BK4588","NVOH","NVO","LU1093756168.USD","LU1093756325.SGD","NVOX","LU0154236417.USD","BK4144","IE00BZ1G4Q59.USD","BK4007","BK4585","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2618963769","title":"諾和諾德旗下「問題」工廠，又一家藥企遭殃","url":"https://stock-news.laohu8.com/highlight/detail?id=2618963769","media":"生物制药小编","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618963769?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 09:20","pubTimestamp":1773192018,"startTime":"0","endTime":"0","summary":"这也是第三家因为该工厂生产设施问题而遭发CRL的药企，其中再生元最为倒霉，2025年，有两款药物皆是因其被拒。2025年10月，同样因为这家工厂的合规性问题，再生元旗下的另一款药物—预填充注射器版本HD Eylea的补充上市申请也遭到拒批，收到FDA的CRL。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","BK4007","LU1093756168.USD","NVO","LU1093756325.SGD","BK4588","IE00BKVL7J92.USD","NVOX","NVOH","IE00BZ1G4Q59.USD","BK4532","BK4585","BK4599"],"gpt_icon":1},{"id":"2618968766","title":"諾和諾德(NVO)股票3月10日盤中下跌3.13%：原因全解讀","url":"https://stock-news.laohu8.com/highlight/detail?id=2618968766","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618968766?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 02:16","pubTimestamp":1773166595,"startTime":"0","endTime":"0","summary":"• FDA就药品不良反应报告违规行为发出警告信。\n• 由于对研发管线和竞争局势的担忧，分析师下调了诺和诺德的评级。\n• 该公司2026财年指引预计销售额和利润将出现下滑。","market":"us","thumbnail":"https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/stocks/261666341-market-movers-nvo-20260310","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","LU1093756325.SGD","BK4007","IE00BZ1G4Q59.USD","LU1093756168.USD","NVOH","NVOX","NVO","BK4532","BK4585","LU0154236417.USD","BK7104","BK4588","BK4599"],"gpt_icon":1},{"id":"2618954420","title":"美股異動丨諾和諾德跌3.3%，因未報告旗下減肥藥的所有疑似副作用接獲FDA警告信","url":"https://stock-news.laohu8.com/highlight/detail?id=2618954420","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618954420?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 23:33","pubTimestamp":1773156833,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","BK4532","LU1093756168.USD","BK4588","BK4585","NVO","NVOH","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4599","LU0154236417.USD","NVOX","LU1093756325.SGD"],"gpt_icon":0},{"id":"2618895342","title":"Hims & Hers與諾和諾德達成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2618895342","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618895342?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 21:03","pubTimestamp":1773147780,"startTime":"0","endTime":"0","summary":"Hims & Hers与诺和诺德结束诉讼，Hims将停止推广复方胰高血糖素样肽-1药物，并通过其平台提供威戈维和奥泽匹克；Hims股价大涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqphnh6182604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HIMS","LU0154236417.USD","BK4007","BK4532","BK4585","LU1093756325.SGD","IE00BKVL7J92.USD","BK4588","IE00BZ1G4Q59.USD","BK4599","NVOH","NVOX","LU1093756168.USD","NVO"],"gpt_icon":0},{"id":"2618933958","title":"跨國藥企2025年成績單：「藥王」易主，創新資產交易創新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2618933958","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618933958?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 17:04","pubTimestamp":1773133472,"startTime":"0","endTime":"0","summary":"随着跨国药企陆续披露2025年业绩报告，全球制药行业的新一轮竞争格局逐步清晰。业绩榜单中，强生以全球941.93亿美元的总营收斩获榜首，旗下创新制药和医疗科技两大核心业务板块分别收入604.01亿美元（+6%）和337.92亿美元（+6.1%）；礼来凭借44%的高增速，实现651.79亿美元的全年营收，成为增速最快的头部药企。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667509930.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667509930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVO","LU1934455863.HKD","LU1093756325.SGD","CDE","LU2361045086.USD","SG9999015358.SGD","IE00BJJMRZ35.SGD","LU2360032135.SGD","GSKH","MRK","BK4588","LU0477156953.USD","SGXZ57979304.SGD","BK4534","LU1983299246.USD","NVOX","LU0130517989.USD","LU0648001328.SGD","LU2125154778.USD","LU2324357040.USD","GSK.UK","IE00B1BXHZ80.USD","LU0320765489.SGD","LU1066051811.HKD","LU0203347892.USD","LU0868494617.USD","IE00BKVL7J92.USD","LU1223082519.USD","LU1989772840.SGD","BK4559","BK4550","BK4585","LU1023059063.AUD","LU2361044865.SGD","LU1291159041.SGD","SG9999014575.USD","IE00BLSP4452.SGD","IE00BN8TJ469.HKD","LU1571399168.USD","LU0289739699.SGD","BK4516","LU0098860793.USD","GSK","LU1066051225.USD","LU0266013472.USD","SG9999001176.USD","SG9999014542.SGD","01477","LU1057294990.SGD","NVOH"],"gpt_icon":1},{"id":"2618217938","title":"Hims & Hers Health盤前續升逾2%，諾和諾德旗下明星減肥藥將登陸平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2618217938","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618217938?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 16:41","pubTimestamp":1773132060,"startTime":"0","endTime":"0","summary":"3月10日消息，美国互联网医疗公司Hims & Hers Health周一股价暴涨超40%，10日盘前续涨2.3%，报22.67美元。原因是诺和诺德宣布将通过Hims平台向美国消费者销售旗下明星减肥药，包括Ozempic和Wegovy注射剂及Wegovy口服片剂，并同步撤回上月提起的专利侵权诉讼。根据双方达成的协议，Hims平台将以诺和诺德自付价格提供这些药物。值得一提的是，诺和诺德此前已将减肥药月费从约1000美元大幅下调至149至299美元区间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031016431197abcc6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031016431197abcc6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HMYY","LU0154236417.USD","LU1093756168.USD","BK4599","HIMS","HIMY","NVOX","BK4532","BK4007","BK4196","IE00BZ1G4Q59.USD","NVOH","LU1093756325.SGD","HIMZ","HIYY","BK4588","IE00BKVL7J92.USD","BK4585"],"gpt_icon":0},{"id":"2618147987","title":"花旗上調Hims & Hers Health(HIMS.US)評級至「中性」 看好諾和諾德協議下的合規溢價","url":"https://stock-news.laohu8.com/highlight/detail?id=2618147987","media":"智通财经","labels":["executive","rating"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618147987?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 16:07","pubTimestamp":1773130046,"startTime":"0","endTime":"0","summary":"花旗银行在最新的研究报告中对这一合作给予了高度评价，并将其视为 Hims & Hers 发展史上的重要转折点。花旗分析师指出，通过引入官方正版药物，Hims & Hers 成功摆脱了长期困扰其业务模式的合规性阴影与法律风险。这一利好消息在二级市场引发了剧烈反弹，Hims & Hers 的股价在消息公布后的交易时段内一度飙升超过 35%，周一收涨40.79%，报22.16美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,rating","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4559","LU0130517989.USD","LU1093756325.SGD","LU0106831901.USD","LU2125154935.USD","LU1244550221.USD","LU2456880835.USD","LU2125154778.USD","BK4599","LU0314106906.USD","BK4196","LU1366192091.USD","LU1267930227.SGD","HMYY","LU0648001328.SGD","LU2360032135.SGD","LU0980610538.SGD","LU1668664300.SGD","LU1093756168.USD","BK4207","HIYY","NVOX","LU0477156953.USD","LU1791807156.HKD","BK4566","LU0128525689.USD","BK4007","HIMZ","BK4532","LU0310800965.SGD","LU2417539215.USD","IE00BKVL7J92.USD","LU1162221912.USD","BK4534","HIMS","LU0320765646.SGD","IE00BSNM7G36.USD","LU2462157665.USD","LU0072461881.USD","LU0052756011.USD","LU0154236417.USD","LU2236285917.USD","HIMY","LU0162691827.USD","BK4504","LU1201861249.SGD","LU0170899867.USD","LU0098860793.USD","BK4585","LU1506573853.SGD","LU1244550494.USD","NVOH","LU0130102774.USD","BK4588","LU1244550577.SGD","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2618672446","title":"3月10日美股成交額前20：HIMS與諾和諾德達成合作，股價大漲逾40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672446","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618672446?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 04:48","pubTimestamp":1773089280,"startTime":"0","endTime":"0","summary":"周一美股成交额第1名英伟达收高2.72%，成交313.6亿美元。亿万富豪廖凯原周一再度增持英伟达，将其持股数量翻倍至200万股。　　摩尔维持对博通的“买入”评级，将其目标价从462美元上调至470美元，意味着约42%的上涨空间。　　此外，3月2日，英伟达宣布投资20亿美元并与Lumentum达成多年战略合作，包括数十亿美元采购高端激光元件的承诺，聚焦AI数据中心光学技术。　　该消息公布后，诺和诺德撤销了对该公司的诉讼，标志着双方争端的结束。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqmumf6558599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HIMZ","LU1093756168.USD","NVOH","LU0154236417.USD","LU1093756325.SGD","NVO","NVOX","BK4588","IE00BZ1G4Q59.USD","BK4585","HIMY","BK4196","IE00BKVL7J92.USD","BK4599","HIMS","BK4007","BK4532","HIYY","HMYY"],"gpt_icon":1},{"id":"2618781516","title":"諾和諾德盤中異動 股價大漲3.00%報39.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618781516","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618781516?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 00:15","pubTimestamp":1773072908,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日00时15分，诺和诺德股票出现异动，股价急速拉升3.00%。截至发稿，该股报39.74美元/股，成交量1310.03万股，换手率0.29%，振幅3.21%。诺和诺德股票所在的制药行业中，整体跌幅为0.48%。诺和诺德公司简介：诺和诺德在全球品牌糖尿病治疗市场中占据大约三分之一的份额，是世界上领先的糖尿病护理产品供应商。诺和诺德还拥有一个生物制药部门，专注于治疗血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310001508a6b30ca2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310001508a6b30ca2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NVO","LU0154236417.USD","BK4585","LU1093756325.SGD","LU1093756168.USD","BK4532","BK4588","IE00BKVL7J92.USD","NVOX","IE00BZ1G4Q59.USD","NVOH","BK4599"],"gpt_icon":1},{"id":"2618621200","title":"分析師：Hims & Hers本身不會通過諾和諾德的GLP-1s藥物盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621200","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621200?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 21:43","pubTimestamp":1773063796,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","BK4007","IE00BKVL7J92.USD","BK4144","BK4585","LU1093756168.USD","BK4588","BK4590","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","BK4599","NVOX","HIMS","NVOH"],"gpt_icon":0},{"id":"1162171962","title":"Hims與諾和諾德合作或引發短期逆風——市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1162171962","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162171962?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 20:53","pubTimestamp":1773060828,"startTime":"0","endTime":"0","summary":"早盘8点49分——Hims & Hers Health Inc.股价因诺和诺德终止对其诉讼并达成合作的消息而大幅飙升。根据协议，Hims平台将引入诺和诺德的GLP-1类药物。Truist分析师指出，尽管此举消除了Hims面临的重要法律风险，但合作可能对其短期业务造成冲击。\n作为协议的一部分，Hims将停止销售复合GLP-1药物，而这类药物曾贡献其大部分营收。不过，品牌GLP-1药物的收入持续性显著更高，尤其考虑到Hims的复合药物此前一直面临法律威胁。分析师认为，这一转变可能促使投资者愿意给予Hims更高估值倍数。受此影响，Hims股价在盘前交易中猛涨51%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMY","BK4007","BK4532","IE00BZ1G4Q59.USD","HIMZ","LU0154236417.USD","HMYY","HIYY","BK4588","BK4585","NVOX","LU1093756168.USD","HIMS","IE00BKVL7J92.USD","LU1093756325.SGD","NVOH","BK4599","BK4196"],"gpt_icon":0},{"id":"2618356626","title":"諾和諾德確認將在HIMS & HERS平台上銷售WEGOVY、OZEMPIC產品。","url":"https://stock-news.laohu8.com/highlight/detail?id=2618356626","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618356626?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 20:31","pubTimestamp":1773059515,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["HIMY","LU0154236417.USD","NVOH","BK4599","IE00BKVL7J92.USD","BK4007","LU1093756325.SGD","HMYY","LU1093756168.USD","HIMS","HIMZ","IE00BZ1G4Q59.USD","BK4532","BK4585","BK4588","NVOX","BK4196","HIYY","NVO"],"gpt_icon":0},{"id":"2618640732","title":"美股異動丨Hims盤前飆漲55%，與諾和諾德達成減肥藥授權協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640732","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640732?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 19:04","pubTimestamp":1773054241,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","BK4007","NVO","BK4599","LU1093756325.SGD","HIMS","LU1093756168.USD","BK4585","NVOH","IE00BKVL7J92.USD","NVOX","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4532"],"gpt_icon":0},{"id":"2617664071","title":"諾和諾德全球首創新藥在華獲批；羅氏公布amylin減重臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2617664071","media":"药创新","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617664071?lang=zh_tw&edition=fundamental","pubTime":"2026-03-08 18:19","pubTimestamp":1772965182,"startTime":"0","endTime":"0","summary":"诺和诺德全球首创新药在华获批，实现“中国首发”；罗氏53亿美元收购的amylin减重管线公布临床数据；国产自免TCE管线授权给优时比；司美格鲁肽在华递交MASH适应症上市申请；RNAi疗法龙头公司Alnylam加码心血管领域；跨国药企中国区迎来重要高管变动……罗氏公布amylin减重II期临床数据3月5日，罗氏公布petrelintide减重II期临床数据：petrelintide每周给药一次，治疗42周时平均减重10.7%。罗氏表示将向监管机构递交fenebrutinib的全部III期数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030818215997aa6a83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030818215997aa6a83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","LU1093756168.USD","BK4599","RHHBY","NVO","BK4585","BK4588","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","NVOX","NVOH","IE00BKVL7J92.USD","BK4007"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":187,"code":"91000000","status":"200"}]}}